Akorn (AKRX) Getting Somewhat Positive Media Coverage, Analysis Shows

News headlines about Akorn (NASDAQ:AKRX) have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akorn earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.1136985667296 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern’s rankings:

Akorn opened at $18.59 on Friday, according to Marketbeat. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.87 and a current ratio of 3.94. Akorn has a 12-month low of $10.76 and a 12-month high of $33.63. The company has a market capitalization of $2.36 billion, a PE ratio of 11.69, a price-to-earnings-growth ratio of 2.96 and a beta of 1.74.

Several brokerages have commented on AKRX. BidaskClub upgraded shares of Akorn from a “strong sell” rating to a “sell” rating in a report on Saturday, April 21st. Zacks Investment Research upgraded shares of Akorn from a “sell” rating to a “hold” rating in a report on Monday, July 9th. Royal Bank of Canada raised their target price on shares of Akorn from $25.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, July 25th. Deutsche Bank reiterated a “hold” rating on shares of Akorn in a report on Monday, April 30th. Finally, ValuEngine downgraded shares of Akorn from a “hold” rating to a “sell” rating in a report on Friday, May 11th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $28.60.

Akorn Company Profile

Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.

Recommended Story: Average Daily Trade Volume – ADTV

Insider Buying and Selling by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply